Methylene Tetrahydrofolate Reductase Gene Polymorphism and the Risk of Ischemic Stroke in Type 2 Diabetic Egyptian Patients

Mackawy, Amal M.H.; Badawy, Mohammad Elsaid

doi:10.5539/gjhs.v3n2p162

Cited by 1 publication

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies, however, included cases with T2DM and serious complications, even when the study purported to assess only the association between the MTHFR SNP and T2DM per se. Therefore we divided the 39 studies into two subgroups: 14 studies that explicitly reported the presence of serious complications among cases or failed to report on such complications at all [8], [21], [22], [27], [28],[30],[43],[45],[46],[48],[50],[51],[58],[60], and 25 studies that explicitly reported the absence of serious complications [7], [26], [29], [31]–[42], [44], [47], [49], [52]–[57], [59]. Meta-analysis of these two subgroups, like the meta-analysis across all included studies, failed to provide clear, consistent evidence that the genotype at MTHFR polymorphism rs1801133 was associated with either increased or reduced risk of T2DM (Table 2).…”

Section: Resultsmentioning

confidence: 99%

“…Most of the studies included in the present systematic review did not analyze Hcy levels in cases and controls, making it difficult to gain a comprehensive picture. Of the studies that did examine whether Hcy levels were associated with the rs1801133 polymorphism, 11 found the TT genotype to be associated with higher Hcy levels than the CT or CC genotypes in patients with T2DM [7], [8], [31], [32], [35], [45], [46], [51], [54], [59], [60], while 6 found no such association [27], [48], [49], [52], [56], [57]. A meta-analysis published in 1998 concluded there was an association between the TT genotype and elevated plasma homocysteine levels in individuals with T2DM [17], while a more recent prospective study found no such association [72].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Methylenetetrahydrofolate Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus

et al. 2013

View full text Add to dashboard Cite

ObjectiveThis review aimed to comprehensively assess the literature examining a possible link between the rs1801133 polymorphism (677C→T) in the gene encoding the methylenetetrahydrofolate reductase (MTHFR) gene and risk of type 2 diabetes mellitus (DM).Research Design and MethodsSeveral research databases were systematically searched for studies examining the genotype at the rs1801133 polymorphism in healthy control individuals and individuals with type 2 DM. Genotype frequency data were examined across all studies and across subsets of studies according to ethnicity and presence of serious DM-related complications. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.ResultsA total of 4855 individuals with type 2 DM and 5242 healthy controls from 15 countries comprising Asian, Caucasian and African ethnicities were found to satisfy the inclusion criteria and included in the review. Genotype at the rs1801133 polymorphism was not consistently associated with either increased or reduced risk of type 2 DM; the OR across all studies was 0.91 (95%CI 0.82 to 1.00) for the C- vs. T-allele, 0.88 (0.75 to 1.03) for CC vs. CT+TT, 0.82 (0.71 to 0.95) for CC vs. TT, and 1.15 (1.03 to 1.29) for TT vs. CC+CT. Similar results were found when the meta-analysis was repeated separately for each ethnic subgroup, and for subgroups with or without serious DM-related complications.ConclusionsThere does not appear to be compelling evidence of an association between the genotype at the rs1801133 polymorphism of the MTHFR gene and risk of type 2 DM.

show abstract